AbCellera Biologics (ABCL) News
NASDAQ: ABCLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
9.69-0.78 (-7.45%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ABCL news summary
We found 4 recent headlines mentioning AbCellera Biologics (ABCL): 0 in the past week and 3 in the past 30 days, most often from Nasdaq, Business Wire. ABCL is making an outsized move today, down 7.45% at $9.69, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "AbCellera (ABCL) Q3 2026 Earnings Call Transcript", was published by Nasdaq on Nov 10, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest AbCellera Biologics headlines
- AbCellera (ABCL) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- AbCellera Biologics Inc Q3 Loss Decreases(RTTNews) - AbCellera Biologics Inc (ABCL) revealed Loss for third quarter of -$40.76 millionNasdaq
- AbCellera Reports Q3 2026 Business ResultsVANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q3 2026 Business ResultsBusiness Wire
- ABCL Stock Surges 121% in 3 Months: Here's What You Need to KnowAbCellera shares skyrocket 121% as positive ABCL635 data, major partnerships and a stronger financial position boost investor confidence.NasdaqABCL, VRTX, JAZZ